ストックスクリーナーアプリを入手
5.49
5.76%
0.28
前日終値:
$5.21
開ける：
$5.23
24時間の取引高:
84,603
Relative Volume:
0.30
時価総額：
$99.29M
収益：
$62.81M
当期純損益:
$-13.75M
株価収益率:
-6.8625
EPS:
-0.8
ネットキャッシュフロー:
$153.00K
1週間 パフォーマンス:
+8.25%
1か月 パフォーマンス:
+6.17%
6か月 パフォーマンス:
-44.90%
1年 パフォーマンス:
-58.73%
1日の値動き範囲:
$5.23
$5.59
1週間の範囲:
$4.80
$5.59
52週間の値動き範囲:
$3.78
$16.64
Optimizerx Corp Stock (OPRX) Company Profile
OPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
5.50 | 99.29M | 62.81M | -13.75M | 153.00K | -0.80 |
|
VEEV
Veeva Systems Inc
|
213.41 | 34.48B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
67.00 | 11.47B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
54.80 | 10.02B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
97.61 | 8.45B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.08 | 6.35B | 906.14M | -52.62M | 89.62M | -0.3621 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | 開始されました | Stephens | Equal-Weight |
| 2024-07-25 | 再開されました | B. Riley Securities | Buy |
| 2024-04-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-01-03 | 開始されました | Barclays | Equal Weight |
| 2023-02-02 | 再開されました | B. Riley Securities | Buy |
| 2022-11-01 | 開始されました | Stifel | Buy |
| 2022-07-15 | 開始されました | SVB Leerink | Outperform |
| 2021-10-18 | 再開されました | B. Riley Securities | Buy |
| 2021-04-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-01-03 | 開始されました | William Blair | Outperform |
すべてを表示
Optimizerx Corp (OPRX) 最新ニュース
OptimizeRx Co. (NASDAQ:OPRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Reviewing OptimizeRx (NASDAQ:OPRX) & Maximus (NYSE:MMS) - Defense World
OptimizeRx price target lowered to $13 from $17 at B. Riley - Yahoo Finance
Lake Street reiterates Buy on OptimizeRx after ‘surprising’ CEO departure - Yahoo Finance
OptimizeRx’s (OPRX) Buy Rating Reaffirmed at Lake Street Capital - Defense World
OptimizeRx (NASDAQ:OPRX) Given New $13.00 Price Target at B. Riley - Defense World
Stifel maintains Buy rating on OptimizeRX stock citing shift to consistent growth strategy - Investing.com India
Lake Street holds OptimizeRX stock at Buy list despite CEO exit - Investing.com Australia
OptimizeRx's (OPRX) Buy Rating Reaffirmed at Lake Street Capital - MarketBeat
Lake Street holds OptimizeRX stock at Buy list despite CEO exit By Investing.com - Investing.com South Africa
OptimizeRx Corp. Announces Chief Executive Officer Changes - Marketscreener.com
OptimizeRX stock retains Buy rating as company transitions to new leadership team - Investing.com
OptimizeRx CEO to step down, interim successor named By Investing.com - Investing.com Australia
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO - EIN News
OptimizeRx CEO to step down, interim successor named - Investing.com
OptimizeRx CEO Steps Down After 9-Year Growth Era; Company Projects Strong 2024 Outlook - StockTitan
OptimizeRx (NASDAQ:OPRX) Research Coverage Started at Stephens - Defense World
OptimizeRx Co. (NASDAQ:OPRX) Stake Increased by BNP Paribas Financial Markets - Defense World
Stephens & Co. Initiates Coverage of OptimizeRx (OPRX) with Equal-Weight Recommendation - MSN
The Analyst Verdict: OptimizeRx In The Eyes Of 6 Experts - Benzinga
OptimizeRx (NASDAQ:OPRX) Earns Equal Weight Rating from Analysts at Stephens - MarketBeat
OptimizeRx CEO William Febbo acquires $100,220 in company shares By Investing.com - Investing.com Australia
OptimizeRx's SWOT analysis: digital health stock faces growth hurdles By Investing.com - Investing.com Canada
OptimizeRx's SWOT analysis: digital health stock faces growth hurdles - Investing.com
OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo Purchases 20,000 Shares - MarketBeat
OptimizeRx CEO William Febbo acquires $100,220 in company shares - Investing.com
OptimizeRx's SWOT analysis: digital health firm's stock faces growth hurdles - Investing.com
AWM Investment Company, Inc. Reduces Stake in OptimizeRx Corp - GuruFocus.com
Quest Partners LLC Buys 9,739 Shares of OptimizeRx Co. (NASDAQ:OPRX) - Defense World
US Penny Stocks To Watch In November 2024 - Simply Wall St
OptimizeRx (OPRX) Surges 19.8%: Is This an Indication of Further Gains? - MSN
OptimizeRx to Participate in Upcoming Investor Conferences - The Manila Times
OptimizeRx to Present at ROTH and Canaccord Genuity Healthcare Conferences in NYC | OPRX Stock News - StockTitan
Janney Montgomery Scott LLC Buys Shares of 104,917 OptimizeRx Co. (NASDAQ:OPRX) - Defense World
Brokerages Set OptimizeRx Co. (NASDAQ:OPRX) Price Target at $11.58 - Defense World
OptimizeRx Corporation (NASDAQ:OPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
AWM Investment Company's Strategic Acquisition of OptimizeRx Cor - GuruFocus.com
Divisadero Street Capital Management's Strategic Acquisition of OptimizeRx Shares - GuruFocus.com
OptimizeRX shares target cut, maintains buy rating on lower revenue - Investing.com
OptimizeRx's (OPRX) "Buy" Rating Reiterated at Roth Mkm - MarketBeat
Optimizerx stock hits 52-week low at $4.69 amid market challenges - Investing.com Nigeria
Earnings call: OptimizeRx reports 30% revenue growth in Q3 By Investing.com - Investing.com UK
OptimizeRx (NASDAQ:OPRX) Price Target Cut to $8.00 by Analysts at Stifel Nicolaus - MarketBeat
JMP Securities Lowers OptimizeRx (NASDAQ:OPRX) Price Target to $8.00 - MarketBeat
OptimizeRx (NASDAQ:OPRX) Given New $5.00 Price Target at Barclays - MarketBeat
OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates - MSN
OptimizeRx Reports Third Quarter 2024 Financial Results - The Manila Times
OptimizeRx Corp (OPRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts ... By GuruFocus - Investing.com Canada
Earnings call: OptimizeRx reports 30% revenue growth in Q3 - Investing.com India
OPTIMIZERx earnings beat by $0.06, revenue fell short of estimates - Investing.com
OptimizeRx Q3 Revenue Jumps 30% to $21.3M, Updates 2024 Guidance | OPRX Stock News - StockTitan
Optimizerx Corp (OPRX) 財務データ
収益
当期純利益
現金流量
EPS
Optimizerx Corp (OPRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Silvestro Stephen L | Chief Commercial Officer |
Dec 19 '24 |
Option Exercise |
0.00 |
6,546 |
0 |
83,424 |
| Besch Doug | Chief Product Officer |
Dec 19 '24 |
Option Exercise |
0.00 |
1,964 |
0 |
12,160 |
| Stelmakh Edward | CFO/COO |
Dec 19 '24 |
Option Exercise |
0.00 |
5,237 |
0 |
38,603 |
| FEBBO WILLIAM J | CEO |
Dec 12 '24 |
Buy |
5.01 |
20,000 |
100,220 |
601,253 |
| Odence-Ford Marion | General Counsel and CCO |
Nov 08 '24 |
Option Exercise |
0.00 |
1,785 |
0 |
24,980 |
| Stelmakh Edward | CFO/COO |
Oct 11 '24 |
Option Exercise |
0.00 |
8,222 |
0 |
35,432 |
| Stelmakh Edward | CFO/COO |
Oct 03 '24 |
Option Exercise |
0.00 |
16,622 |
0 |
31,387 |
| Odence-Ford Marion | General Counsel and CCO |
Oct 03 '24 |
Option Exercise |
0.00 |
6,649 |
0 |
25,147 |
| Silvestro Stephen L | Chief Commercial Officer |
Oct 03 '24 |
Option Exercise |
0.00 |
6,649 |
0 |
79,495 |
| Besch Doug | Chief Product Officer |
Oct 03 '24 |
Option Exercise |
0.00 |
3,324 |
0 |
11,172 |
1.66%
1.04%
大文字化:
|
ボリューム (24 時間):